Bryostatin 1 In Treating Patients With Progressive Kidney Cancer

Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer

NCT00496756 ·Status: TERMINATED ·Phase: PHASE2

A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT05119335 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma

NCT00059735 ·Status: COMPLETED ·Phase: PHASE2

Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer

NCT00005027 ·Status: COMPLETED ·Phase: PHASE2

Chemotherapy in Treating Patients With Advanced Kidney Cancer

NCT00011973 ·Status: COMPLETED ·Phase: PHASE2

PS-341 in Treating Patients With Metastatic Kidney Cancer

NCT00025376 ·Status: COMPLETED ·Phase: PHASE2

A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer

NCT00715182 ·Status: COMPLETED ·Phase: PHASE1

Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer

NCT00016939 ·Status: COMPLETED ·Phase: PHASE2

CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition

NCT04322955 ·Status: RECRUITING ·Phase: PHASE2

Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer

NCT00121251 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment

NCT00009919 ·Status: TERMINATED ·Phase: PHASE2

Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer

NCT04022343 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer.

NCT00656734 ·Status: COMPLETED ·Phase: PHASE1

Research Study for Patients With Metastatic Renal Cell Carcinoma

NCT00110344 ·Status: TERMINATED ·Phase: PHASE2

A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer

NCT00448721 ·Status: COMPLETED ·Phase: PHASE2

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

NCT01575548 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.

NCT00077974 ·Status: COMPLETED ·Phase: PHASE2

Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

NCT01239342 ·Status: TERMINATED ·Phase: PHASE2

A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread

NCT04540705 ·Status: COMPLETED ·Phase: PHASE1

Ph II Study of Perifosine for Patients With Carcinoma of the Kidney

NCT00498966 ·Status: COMPLETED ·Phase: PHASE2

Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma

NCT00044564 ·Status: COMPLETED ·Phase: PHASE2

Phase I Study of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT06175780 ·Status: RECRUITING ·Phase: PHASE1

Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer

NCT00054886 ·Status: COMPLETED ·Phase: PHASE2

A Research Study for Patients With Metastatic Renal Cell Carcinoma

NCT00106613 ·Status: COMPLETED ·Phase: PHASE2

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

NCT03055013 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3